NSE · ZIMLAB
Zim Laboratories Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹93 Cr with net profit ₹-4 Cr — a -4.17% net margin, versus 1.51% the period before.
Shareholding
As of 2026-06-30
- Promoter30.36%
- Public68.28%
- FII0.03%
- DII1.33%
14,510 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.44× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #57 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,516 Cr | 35.34 | 5.34 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,11,501 Cr | 22.84 | 4.11 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,10,943 Cr | 31 | 3.22 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,05,091 Cr | 96.1 | 19.83 | 16.77% | 15.04% |
| Aurobindo Pharma Ltd. | ₹95,996 Cr | 25.39 | 2.53 | 9.25% | 10.7% |
| Dr Reddys Laboratories Ltd. | ₹95,404 Cr | 29.61 | 2.51 | 11.07% | 9.73% |
| Lupin Limited | ₹95,011 Cr | 15.95 | 4.23 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹92,456 Cr | 43.34 | 5.67 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,157 Cr | 21.84 | 6.48 | 28.08% | 10.22% |
| Biocon Ltd. | ₹63,558 Cr | 87.05 | 1.84 | 1.14% | 2.89% |
| Zim Laboratories Limited(this company) | ₹732 Cr | 197.72 | 2.49 | 1.97% | 0.93% |
AI analysis
AI-generated · google/gemini-2.5-flashZim Laboratories Limited (ZIMLAB) has a market capitalization of Rs 649 Cr. The company reported revenue of Rs 385.78 Cr with a profit margin of 156.3%. Its P/E ratio stands at 149.38 and its EPS at 0.81. The company's stock has a 52-week high of Rs 133.9 and a 52-week low of Rs 59.31.
Positives
- +The return on equity (ROE) is high at 197.1%.
- +The profit margin is significantly high at 156.3%.
- +The debt-to-equity ratio is moderate at 0.45.
Negatives
- −Revenue growth for the last fiscal year was negative at -1.2%.
- −The promoter shareholding decreased from 33.5163% in May 2018 to 30.3582% in June 2026.
- −The company recorded a net loss in the quarter ending June 2025 of -Rs 1.87 Cr and in September 2025 of -Rs 0.42 Cr.
- −The P/E ratio of 149.38 is relatively high.
- −The company is currently under ESM Stage 2 surveillance.
Financial Performance
Zim Laboratories Limited reported an annual revenue of Rs 385.78 Cr. However, overall revenue growth was -1.2%. The company's net profit for the fiscal year ending March 2026 was Rs 5.8381 Cr, representing an EPS of 1.19. In the quarter ending March 2026, revenue was Rs 105.27 Cr with a net profit of Rs 3.74 Cr.
Profitability & Returns
The company recorded a profit margin of 156.3%. Return on equity (ROE) is 197.1%, while return on capital employed (ROCE) is 5.0661%. The EPS for the last fiscal year was 0.81. The P/E ratio is 149.38, and the book value per share is Rs 54.77.
Balance Sheet
Zim Laboratories Limited has a debt-to-equity ratio of 0.45, indicating a moderate level of debt relative to its equity. The book value per share is Rs 54.77. Further details regarding assets and liabilities are not available in the provided data.
Ownership & Pledges
As of June 30, 2026, promoters held 30.3582% of the shares. Public shareholding was 68.2782%, DIIs held 1.3325%, and FIIs held 0.0311%. There were no promoter pledges reported. The total number of shareholders was 14,510.
Regulatory & Surveillance
Zim Laboratories Limited is currently under ESM (Enhanced Surveillance Measure) Stage 2. This signifies that the stock is subject to specific regulatory monitoring due to factors like price volatility or other risk parameters.
Data as of — price: 2026-09-10 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.